Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients
Completed · Phase 3
Conditions studied: Anemia
In brief
The Objective of this study is to study the safety of FCM in patients with anemia caused by Heavy Uterine Bleeding and the Post Partum state.
Key facts
- Study ID
- NCT00548860
- Run by
- American Regent, Inc.
- People needed
- 2018
- Starts
- 2007-10-01
- Expected to finish
- 2009-07-01
- Last updated by the study team
- 2018-02-20
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Female with iron deficiency anemia
- Hg </= 11 g/dL
You may not qualify if…
- Previous participation in a FCM trial
- Known Hypersensitivity to FCM
- History of anemia other that anemia due to heavy uterine bleeding or the post partum state
- current history of GI bleeding
- Received IV Iron within the month prior
- Anticipated need for surgery
- Malignancy history
- AST or ALT greater than normal
- Received an investigational drug within 30 days of screening
- Pregnant or sexually active females who are not willing ot use an effective form of birth control
Where it is running
- Luitpold Pharmaceuticals — Norristown, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.